Brief: Insilico Medicine Cayman Topco Says Co And CMS Enter Additional Drug Development Collaboration
13/07/2026 02:32
BRIEF-Insilico Medicine Cayman Topco Says Co And CMS Enter Additional Drug Development Collaboration July 13 (Reuters) - Insilico Medicine Cayman TopCo 3696.HK:
CO AND CMS ENTER ADDITIONAL DRUG DEVELOPMENT COLLABORATION IN CENTRAL NERVOUS SYSTEM DISEASES
ELIGIBLE TO RECEIVE MILESTONE PAYMENTS TOTALING UP TO RMB1.2 BILLION
INSILICO MEDICINE IS ELIGIBLE TO RECEIVE MILESTONE PAYMENTS TOTALING UP TO APPROXIMATELY RMB1.2 BILLION
Further company coverage: 3696.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insilico Medicine Cayman TopCo
See all newsInSilico Medicine jumps on progress in testing of new weight-loss drug
Development Collaboration
InSilico jumps on collaboration to develop biological frontier foundation models
HK-listed InSilico Medicine climbs as chairman buys shares
Brief: Insilico Medicine Cayman Topco's Chair Purchases Aggregate 113,500 Shares In Sept 4-7